Nurix Therapeutics, Inc. (NRIX)
26.27
-0.45
(-1.68%)
USD |
NASDAQ |
Aug 24, 16:00
26.35
+0.08
(+0.30%)
After-Hours: 07:56
Nurix Therapeutics Shareholders Equity (Quarterly) : 402.63M for May 31, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| May 31, 2026 | 402.63M |
| February 28, 2026 | 480.89M |
| November 30, 2025 | 538.75M |
| August 31, 2025 | 372.25M |
| May 31, 2025 | 447.60M |
| February 28, 2025 | 480.92M |
| November 30, 2024 | 526.99M |
| August 31, 2024 | 376.86M |
| May 31, 2024 | 370.69M |
| February 29, 2024 | 168.75M |
| November 30, 2023 | 200.49M |
| August 31, 2023 | 233.82M |
| May 31, 2023 | 259.92M |
| February 28, 2023 | 274.05M |
| Date | Value |
|---|---|
| November 30, 2022 | 303.70M |
| August 31, 2022 | 342.54M |
| May 31, 2022 | 266.74M |
| February 28, 2022 | 305.92M |
| November 30, 2021 | 342.30M |
| August 31, 2021 | 375.22M |
| May 31, 2021 | 398.18M |
| February 28, 2021 | 270.13M |
| November 30, 2020 | 290.27M |
| August 31, 2020 | 307.62M |
| May 31, 2020 | -61.53M |
| February 29, 2020 | -69.80M |
| November 30, 2019 | -9.519M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Monte Rosa Therapeutics, Inc. | 487.28M |
| Gilead Sciences, Inc. | 11.83B |
| TG Therapeutics, Inc. | 604.08M |
| Cue Biopharma, Inc. | 2.31M |
| Keros Therapeutics, Inc. | 262.32M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 535.54M |
| Total Liabilities (Quarterly) | 132.91M |
| Debt to Equity Ratio | 0.1444 |
| Current Ratio | 6.338 |
| Net Debt Paydown Yield | -0.34% |